
MiNK Therapeutics (INKT) Stock Forecast & Price Target
MiNK Therapeutics (INKT) Analyst Ratings
Bulls say
MiNK Therapeutics is expected to have a positive outlook as the company has successfully entered into a collaboration with C-Further to further develop and fund their PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers. The company's financials show potential for increased operating expenses in 2026 as they initiate phase 2b/3 trials, but with $13.4M in cash and non-dilutive funding received, the company is well-funded to support their operations until late 2026/early 2027. The inherent advantages of iNKT cell therapies over traditional treatments make MiNK a promising player in the biopharmaceutical industry.
Bears say
MiNK Therapeutics is in the early stages of its development and is currently focused on initiating a Phase 2 clinical trial for severe pulmonary diseases and GvHD. With no approved therapies currently available and positive survival data in previous studies, the company has low bar for success. However, the expected trial size, funding source, and potential collaboration with ImmunityBio suggest a potential for external capital to be used, which may impact the company's overall financial health.
This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
MiNK Therapeutics (INKT) Analyst Forecast & Price Prediction
Start investing in MiNK Therapeutics (INKT)
Order type
Buy in
Order amount
Est. shares
0 shares